Authors

• Jorge J. Castillo (ORCID: https://orcid.org/0000-0001-9490-7532)
• Zachary R. Hunter (ORCID: https://orcid.org/0000-0002-1689-1691)
• Christopher J. Patterson (ORCID: https://orcid.org/0000-0002-9652-2203)
• Andrew R. Branagan (ORCID: https://orcid.org/0000-0002-3868-9267)
• Gottfried von Keudell (ORCID: https://orcid.org/0000-0001-7254-5374)
• Amanda Kofides
• Catherine Flynn (ORCID: https://orcid.org/0000-0001-7645-3469)
• Maria Luisa Guerrera (ORCID: https://orcid.org/0000-0002-0730-4678)
• Nickolas Tsakmaklis
• Shayna Sarosiek (ORCID: https://orcid.org/0000-0002-0075-6735)
• Kirsten Meid
• Steven P. Treon (ORCID: https://orcid.org/0000-0001-6393-6154)
• Kris Richardson
• Alexandra Eurell
• Andres Ramirez‐Gamero
• Xia Liu (ORCID: https://orcid.org/0000-0003-4177-6158)
• Shirong Liu (ORCID: https://orcid.org/0000-0002-3821-9134)
• Nina Budano

Institutions

• Beth Israel Deaconess Medical Center (US)
• Massachusetts General Hospital (US)
• Dana-Farber Cancer Institute (US)

Publication Details

Journal

Blood

Published

2024-11-05

DOI

https://doi.org/10.1182/blood-2024-198297

Citations

8

Primary Topic

Chronic Lymphocytic Leukemia Research

Type

article

Field-Weighted Citation Impact

3.50

Funders

• Eli Lilly and Company
• AstraZeneca
• CSL Behring
• Regeneron Pharmaceuticals
• National Comprehensive Cancer Network
• BeiGene
• Pharmacyclics